Xeris Biopharma Holdings (XERS) EBITDA Margin Growth (1y) (2021 - 2026)
Xeris Biopharma Holdings (XERS) EBITDA Margin Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 304.00 |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | -157.00 |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | -650.00 |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | -3,172.00 |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 2,080.00 |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 152.00 |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -17,785.00 |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | -583.00 |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -2,472.00 |
| 10 | Xeris Biopharma Holdings | 1.07 Bn | 954.87 Mn | 72.55 Mn | 1,802.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,802.00 |
| Dec 31, 2025 | 2,144.00 |
| Sep 30, 2025 | 2,981.00 |
| Jun 30, 2025 | 2,851.00 |
| Mar 31, 2025 | 3,140.00 |
| Dec 31, 2024 | 2,159.00 |
| Sep 30, 2024 | -381.00 |
| Jun 30, 2024 | 2,113.00 |
| Mar 31, 2024 | 400.00 |
| Dec 31, 2023 | 886.00 |
| Sep 30, 2023 | 4,823.00 |
| Jun 30, 2023 | 5,108.00 |
| Mar 31, 2023 | 10,217.00 |
| Dec 31, 2022 | 19,807.00 |
| Sep 30, 2022 | 16,182.00 |
| Jun 30, 2022 | 20,564.00 |
| Mar 31, 2022 | 7,196.00 |
| Dec 31, 2021 | 7,348.00 |
| Sep 30, 2021 | -6,393.00 |